Is Aclaris Therapeutics, Inc. (ACRS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 30.7% / 30% | 0.1% / 30% | 424.88% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 30.7% / 33% | 0.1% / 33% | 424.88% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 51.6% / 33% | 0.1% / 33% | 424.88% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 30.7% / 33% | 0.1% / 33% | 424.88% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 51.6% / 33% | 0.1% / 50% | 424.88% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1724.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -50.2% | |
| Return on Assets (ROA) | -24.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$47M |
| Free Cash Flow | -$47M |
| Debt-to-Equity | 2.1 |
| Current Ratio | 3.4 |
| Total Assets | $160M |
Price & Trading
| Last Close | $3.52 |
| 50-Day MA | $3.49 |
| 200-Day MA | $2.46 |
| Avg Volume | 2.3M |
| Beta | 0.9 |
|
52-Week Range
$1.05
| |
About Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aclaris Therapeutics, Inc. (ACRS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aclaris Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aclaris Therapeutics, Inc.'s debt ratio?
Aclaris Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Aclaris Therapeutics, Inc.'s key financial metrics?
Aclaris Therapeutics, Inc. has a market capitalization of $426M, and revenue of $8M. Return on equity stands at -50.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.